本帖最后由 老马 于 2012-1-13 21:20 编辑
. v7 f: g+ u3 @! J% }# `" H$ n0 Q
/ k7 ]; m' K! F+ {% M爱必妥和阿瓦斯丁的比较
9 {+ c. Z2 A* h* j+ \2 R
L( t+ D2 k6 z2 `
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
; f5 q' l) D/ h- M
" |8 G+ j% {$ [1 Z6 f
4 i5 \' ?4 h. k
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
2 S# ~) C0 i# V O2 W9 h==================================================; J& w! p& n! c3 F) ^( C8 t2 x
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# G" I: S9 j, t6 J, a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.1 i7 X! @7 I& Q W# P
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.4 c S0 @* h0 T) o# z8 e4 M
|